Supporting Biosimilar and Protein Characterization Complexity with Novel Bio-Inert Hardware and New LC bioZen Column Portfolio
23 May 2018

One concern when performing analytical LC method development for proteins is non-specific protein adsorption. Priming of columns before analysis is a common practice to improve protein recovery that can be labor and time intensive, and can vary from column to column resulting in reproducibility and carryover concerns. In this webinar, we will introduce a novel bio-inert column hardware to mitigate these issues and improve both the robustness and quality of methods and data.

As the complexity of biotherapeutics and biosimilars continues to increase, so to has the levels characterization needed. To support this shift we designed an LC column portfolio packed in bio-inert hardware, based on two high efficiency, yet complementary particle platforms and a flexible collection of orthogonal surface chemistries. This new HPLC/UHPLC column portfolio for biologics, aptly named bioZen, focuses on providing improved reproducibility, resolution and performance across major protein characterization techniques.

Key Learning Objectives:

  • The impact of hardware on sample recovery and priming
  • New HPLC and UHPLC portfolio for analysis of mAbs, ADCs and impurities
  • High molecular aggregate characterization and improved recovery with unique thermally modified fully porous SEC columns
  • Improvements in peptide mapping using orthogonal selectivities and particle platforms
  • Top- and middle- down approaches for antibody characterization including average DAR by reversed phase
  • A novel core-shell HILIC stationary phase that offers differentiated released glycan retention profile
Who Should Attend:
  • Anyone characterizing mAbs, ADCs or biotherapeutics by HPLC/UHPLC
  • Anyone new to the characterization of proteins by SEC, RP, HILIC or IEX
  • Anyone who has a bio-inert UHPLC system
  • Anyone interested in novel HILIC chemistries for N-linked glycan analysis

Phenomenex Inc